{
  "ticker": "SGMT",
  "company_name": "Sagimet Biosciences Inc. - Seri",
  "success": true,
  "trials": [
    {
      "nct_id": "NCT04906421",
      "title": "Study of TVB-2640 in Subjects With Nonalcoholic Steatohepatitis (NASH)",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease",
      "start_date": "2021-08-12",
      "completion_date": "2023-10-02",
      "enrollment": 0,
      "sponsor": "Sagimet Biosciences Inc."
    },
    {
      "nct_id": "NCT07216313",
      "title": "A Drug-Drug Interaction Study of Denifanstat and Resmetirom in Healthy Adult Participants",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy",
      "start_date": "2025-09-30",
      "completion_date": "2025-10-20",
      "enrollment": 0,
      "sponsor": "Sagimet Biosciences Inc."
    },
    {
      "nct_id": "NCT06594523",
      "title": "A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASH and F2/F3 Fibrosis",
      "status": "WITHDRAWN",
      "phase": "PHASE3",
      "condition": "MASH, NASH, Metabolic Dysfunction-associated Steatohepatitis, Noncirrhotic Metabolic Dysfunction-associated Steatohepatitis, Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver",
      "start_date": "2025-03",
      "completion_date": "2030-12",
      "enrollment": 0,
      "sponsor": "Sagimet Biosciences Inc."
    },
    {
      "nct_id": "NCT06692283",
      "title": "A Phase 3 Study Evaluating the Safety and Efficacy of Denifanstat in Patients With MASLD and MASH",
      "status": "WITHDRAWN",
      "phase": "PHASE3",
      "condition": "MASLD, MASH, NASH, Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver",
      "start_date": "2025-03",
      "completion_date": "2027-06",
      "enrollment": 0,
      "sponsor": "Sagimet Biosciences Inc."
    },
    {
      "nct_id": "NCT05657834",
      "title": "Open-label Study of the Absorption, Metabolism, and Excretion of [14C]TVB-2640 Following a Single Oral Dose in Healthy Male Subjects",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Healthy Volunteers",
      "start_date": "2022-11-21",
      "completion_date": "2022-12-21",
      "enrollment": 0,
      "sponsor": "Sagimet Biosciences Inc."
    },
    {
      "nct_id": "NCT03938246",
      "title": "Study of TVB-2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH)",
      "status": "COMPLETED",
      "phase": "PHASE2",
      "condition": "MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)",
      "start_date": "2019-03-22",
      "completion_date": "2021-10-02",
      "enrollment": 0,
      "sponsor": "Sagimet Biosciences Inc."
    },
    {
      "nct_id": "NCT05835180",
      "title": "A Phase I Pharmacokinetic Study of TVB-2640 (Denifanstat) in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared to Subjects With Normal Hepatic Function",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Non-alcoholic Steatohepatitis, Hepatic Impairment, Cirrhosis",
      "start_date": "2023-05-01",
      "completion_date": "2023-12-18",
      "enrollment": 0,
      "sponsor": "Sagimet Biosciences Inc."
    },
    {
      "nct_id": "NCT05743621",
      "title": "Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Prostatic Neoplasms, Castration-Resistant",
      "start_date": "2023-11-20",
      "completion_date": "2029-01-25",
      "enrollment": 0,
      "sponsor": "Weill Medical College of Cornell University"
    },
    {
      "nct_id": "NCT02223247",
      "title": "A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors",
      "status": "COMPLETED",
      "phase": "PHASE1",
      "condition": "Solid Malignant Tumor",
      "start_date": "2013-11",
      "completion_date": "2017-06",
      "enrollment": 0,
      "sponsor": "Sagimet Biosciences Inc."
    },
    {
      "nct_id": "NCT06989840",
      "title": "Phase 1 Study to Evaluate the Safety, Tolerability, PK, and PD of TVB-3567 in Healthy Participants With or Without Acne",
      "status": "RECRUITING",
      "phase": "PHASE1",
      "condition": "Acne",
      "start_date": "2025-05-19",
      "completion_date": "2026-01-01",
      "enrollment": 0,
      "sponsor": "Sagimet Biosciences Inc."
    }
  ],
  "summary": {
    "total_trials": 12,
    "by_phase": {
      "PHASE2": 3,
      "PHASE1": 6,
      "PHASE3": 2,
      "PHASE1, PHASE2": 1
    },
    "by_status": {
      "COMPLETED": 7,
      "WITHDRAWN": 2,
      "RECRUITING": 2,
      "ACTIVE_NOT_RECRUITING": 1
    },
    "active_trials": 3,
    "completed_trials": 7,
    "conditions": [
      "Acne",
      "Healthy",
      "Healthy Volunteers",
      "KRAS Gene Mutation",
      "MASH, NASH, Metabolic Dysfunction-associated Steatohepatitis, Noncirrhotic Metabolic Dysfunction-associated Steatohepatitis, Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver",
      "MASLD, MASH, NASH, Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis, Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver",
      "MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)",
      "Metabolic Dysfunction-assocated Steatohepatitis/ Nonalcoholic Fatty Liver Disease",
      "Metabolic Syndrome",
      "Non-alcoholic Steatohepatitis, Hepatic Impairment, Cirrhosis",
      "Prostatic Neoplasms, Castration-Resistant",
      "Solid Malignant Tumor"
    ],
    "lead_stage": "phase_3"
  },
  "provenance": {
    "source": "ClinicalTrials.gov API v2",
    "timestamp": "2026-01-29T12:21:49.868317",
    "search_query": "Sagimet Biosciences Inc. - Seri",
    "url": "https://clinicaltrials.gov/search?term=Sagimet+Biosciences+Inc.+-+Seri"
  }
}